We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Early Immunogenicity Risk Mitigation

Early Immunogenicity Risk Mitigation content piece image
The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems.

Implementing early immunogenicity assessment strategies using tools like in silico T cell epitope prediction and in vitro T cell assays can contribute significantly to the successful outcome of drug development programs and reduce the number of product failures.